Rivoceranib

Generic Name: Rivoceranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

Phase 2

Suspended

Conditions: Effect of Drug
Toxicity, Drug

Interventions: Drug: apatinib

First Posted Date: 2021-04-01

Last Posted Date: 2024-05-14

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 44

Registration Number: NCT04824352

Locations: 🇨🇳
Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Phase 2

Completed

Conditions: Biliary Tract Cancer
Anti-PD-1 Therapy
Targeted Molecular Therapy
Capecitabine

Interventions: Drug: Camrelizumab
Drug: apatinib
Drug: Capecitabine

First Posted Date: 2021-01-22

Last Posted Date: 2024-01-30

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 28

Registration Number: NCT04720131

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Phase 2

Withdrawn

Conditions: ICC

Interventions: Drug: Systemic Chemotherapy
Drug: Sintilimab
Drug: Apatinib

First Posted Date: 2020-12-23

Last Posted Date: 2021-02-04

Lead Sponsor: Sun Yat-sen University

Registration Number: NCT04682249

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Phase 2

Conditions: Advanced Non Squamous NSCLC

Interventions: Drug: Camrelizumab
Drug: Apatinib

First Posted Date: 2020-12-17

Last Posted Date: 2021-06-29

Lead Sponsor: Junling Li

Target Recruit Count: 30

Registration Number: NCT04670913

Locations: 🇨🇳
China, Beijing, Beijing, China

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Phase 1

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Drug: Fluzoparib
Drug: Apatinib

First Posted Date: 2020-12-09

Last Posted Date: 2020-12-09

Lead Sponsor: Tianjin Medical University Second Hospital

Target Recruit Count: 53

Registration Number: NCT04659785

Locations: 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Phase 2

Conditions: Solid Tumor

Interventions: Radiation: radiotherapy
Drug: irinotecan liposome
Drug: apatinib
Drug: PD-1 antibody

First Posted Date: 2020-09-30

Last Posted Date: 2020-09-30

Lead Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Target Recruit Count: 30

Registration Number: NCT04569916

Locations: 🇨🇳
Nanjing Drum Tower Hospital, The Affiliated of Nanjing University Medical School, Nanjing, Jiangsu, China

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Not Applicable

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Camrelizumab
Device: TACE
Drug: Apatinib

First Posted Date: 2020-09-23

Last Posted Date: 2023-12-18

Lead Sponsor: Zhongda Hospital

Target Recruit Count: 188

Registration Number: NCT04559607

Locations: 🇨🇳
Zhongda Hospital, Nanjing, Jiangsu, China

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Camrelizumab
Drug: Apatinib

First Posted Date: 2020-09-14

Last Posted Date: 2020-09-14

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 25

Registration Number: NCT04548271

Locations: 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Camrelizumab
Drug: Apatinib

First Posted Date: 2020-09-14

Last Posted Date: 2020-09-14

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 27

Registration Number: NCT04547088

Locations: 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: NSCLC

Interventions: Drug: SHR-1210
Drug: Apatinib

First Posted Date: 2020-08-10

Last Posted Date: 2020-09-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 74

Registration Number: NCT04506242

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy